PHK
NRIX icon

Point72 Hong Kong’s Nurix Therapeutics NRIX Stock Holding History

Point72 Hong Kong’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-992
Closed -$11.3K – 584
2025
Q2 		$11.3K Buy
+992
New +$10.7K ﹤0.01% 405
2022
Q4 		– Sell
-19
Closed – – 1166
2022
Q3 		$0 Buy
+19
New +$301 ﹤0.01% 2256
2022
Q2 		– Sell
-1,109
Closed -$16K – 2263
2022
Q1 		$16K Buy
1,109
+844
+318% +$15K ﹤0.01% 1554
2021
Q4 		$8K Buy
+265
New +$8.03K ﹤0.01% 1685
2021
Q3 		– Sell
-116
Closed -$3K – 2305
2021
Q2 		$3K Sell
116
-264
-69% -$7.75K ﹤0.01% 1821
2021
Q1 		$12K Buy
+380
New +$14.4K ﹤0.01% 1567

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's NRIX Position: Q3 2025 in Review

Point72 Hong Kong sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 992 shares — an estimated $11.3K sold.

Point72 Hong Kong first reported a position in NRIX in Q1 2021 and held it in 6 quarters. The position peaked at $16K in Q1 2022. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Point72 Hong Kong reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 992 Nurix Therapeutics shares in Q3 2025, an estimated $11.3K.
  • Point72 Hong Kong first reported a position in Nurix Therapeutics in Q1 2021 and held it in 6 quarters.
  • Point72 Hong Kong's Nurix Therapeutics position peaked at $16K in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.